186 related articles for article (PubMed ID: 10371693)
1. Extra-adrenal mineralocorticoids and cardiovascular tissue.
Slight SH; Joseph J; Ganjam VK; Weber KT
J Mol Cell Cardiol; 1999 Jun; 31(6):1175-84. PubMed ID: 10371693
[TBL] [Abstract][Full Text] [Related]
2. Mineralocorticoids and cardiovascular diseases. Status of knowledge from experimental and clinical studies.
Pasquale PD; Stefano GD; Paterna S
Ital Heart J; 2000 Sep; 1(9):595-604. PubMed ID: 11130838
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of tissue repair by spironolactone: role of mineralocorticoids in fibrous tissue formation.
Slight SH; Chilakamarri VK; Nasr S; Dhalla AK; Ramires FJ; Sun Y; Ganjam VK; Weber KT
Mol Cell Biochem; 1998 Dec; 189(1-2):47-54. PubMed ID: 9879653
[TBL] [Abstract][Full Text] [Related]
4. Induction of cardiac fibrosis by aldosterone.
Lijnen P; Petrov V
J Mol Cell Cardiol; 2000 Jun; 32(6):865-79. PubMed ID: 10888242
[TBL] [Abstract][Full Text] [Related]
5. Aldosterone: from biosynthesis to non-genomic action onto the proteome.
Zöllner S; Hwang KH; Wilzewski B; Carapito C; Leize-Wagner E; Van Dorsselaer A; Bernhardt R
Steroids; 2008 Oct; 73(9-10):966-72. PubMed ID: 18280527
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells.
Jaffe IZ; Mendelsohn ME
Circ Res; 2005 Apr; 96(6):643-50. PubMed ID: 15718497
[TBL] [Abstract][Full Text] [Related]
7. Aldosterone synthase (CYP11B2) expression and myocardial fibrosis in the failing human heart.
Satoh M; Nakamura M; Saitoh H; Satoh H; Akatsu T; Iwasaka J; Masuda T; Hiramori K
Clin Sci (Lond); 2002 Apr; 102(4):381-6. PubMed ID: 11914098
[TBL] [Abstract][Full Text] [Related]
8. Adrenalectomy amplifies aldosterone induced injury in cardiovascular tissue: an effect attenuated by adrenally derived steroids.
Brem AS; Morris DJ; Li X; Ge Y; Shaw S; Gong R
Steroids; 2013 Mar; 78(3):347-55. PubMed ID: 23287650
[TBL] [Abstract][Full Text] [Related]
9. Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure.
Bauersachs J; Fraccarollo D
Minerva Cardioangiol; 2003 Apr; 51(2):155-64. PubMed ID: 12783071
[TBL] [Abstract][Full Text] [Related]
10. Mineralocorticoid receptor antagonist spironolactone prevents pig serum-induced hepatic fibrosis in rats.
Fujisawa G; Muto S; Okada K; Kusano E; Ishibashi S
Transl Res; 2006 Sep; 148(3):149-56. PubMed ID: 16938653
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of mineralocorticoid receptor-mediated cardiac fibrosis and vascular inflammation.
Young MJ
Curr Opin Nephrol Hypertens; 2008 Mar; 17(2):174-80. PubMed ID: 18277151
[TBL] [Abstract][Full Text] [Related]
12. Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure.
Dieterich HA; Wendt C; Saborowski F
Fiziol Cheloveka; 2005; 31(6):97-105. PubMed ID: 16366159
[TBL] [Abstract][Full Text] [Related]
13. Role of aldosterone in angiotensin II-induced cardiac and aortic inflammation, fibrosis, and hypertrophy.
Neves MF; Amiri F; Virdis A; Diep QN; Schiffrin EL;
Can J Physiol Pharmacol; 2005 Nov; 83(11):999-1006. PubMed ID: 16391708
[TBL] [Abstract][Full Text] [Related]
14. Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage.
Fiebeler A; Nussberger J; Shagdarsuren E; Rong S; Hilfenhaus G; Al-Saadi N; Dechend R; Wellner M; Meiners S; Maser-Gluth C; Jeng AY; Webb RL; Luft FC; Muller DN
Circulation; 2005 Jun; 111(23):3087-94. PubMed ID: 15939810
[TBL] [Abstract][Full Text] [Related]
15. Aldosterone as a cardiovascular risk factor.
Rossi G; Boscaro M; Ronconi V; Funder JW
Trends Endocrinol Metab; 2005 Apr; 16(3):104-7. PubMed ID: 15808807
[TBL] [Abstract][Full Text] [Related]
16. Is aldosterone synthesized within the rat brain?
Gomez-Sanchez EP; Ahmad N; Romero DG; Gomez-Sanchez CE
Am J Physiol Endocrinol Metab; 2005 Feb; 288(2):E342-6. PubMed ID: 15479953
[TBL] [Abstract][Full Text] [Related]
17. Rapid effects of aldosterone on vascular cells: clinical implications.
Lösel R; Schultz A; Boldyreff B; Wehling M
Steroids; 2004 Aug; 69(8-9):575-8. PubMed ID: 15288772
[TBL] [Abstract][Full Text] [Related]
18. Central hypertensive effects of aldosterone.
Gómez-Sánchez EP
Front Neuroendocrinol; 1997 Oct; 18(4):440-62. PubMed ID: 9344633
[TBL] [Abstract][Full Text] [Related]
19. Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats.
Taira M; Toba H; Murakami M; Iga I; Serizawa R; Murata S; Kobara M; Nakata T
Eur J Pharmacol; 2008 Jul; 589(1-3):264-71. PubMed ID: 18582458
[TBL] [Abstract][Full Text] [Related]
20. Aldosterone, mineralocorticoid receptors and vascular inflammation.
Funder JW
Mol Cell Endocrinol; 2004 Mar; 217(1-2):263-9. PubMed ID: 15134827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
